Introduction
============

Vincristine sulfate (VCR) remains a potent and widely used antitumor agent for more than 50 years ([@B12]) and it has significant activity against a non-Hodgkin lymphoma (NHL) subtypes and acute lymphoblastic leukemia (ALL) ([@B8]). VCR exhibits cell cycle-specific cytotoxic activity by binding to tubulin, resulting in microtubule depolymerization, metaphase arrest and apoptosis in cells ([@B19]; [@B17], [@B16]). Thus, the antitumor efficiency of VCR is dependent on the drug concentration and duration of exposure at the tumor site ([@B10]). However, the routinely individual standard VCR dose is limited to 1.4 mg/m^2^ or a maximum 2 mg (i.e., dose capping) in most VCR-containing cancer treatment regimens in order to reduce the risk of severe peripheral and central nervous system (CNS) neurotoxicity ([@B9]; [@B15]), which may limit its optimal clinic benefit.

Liposomes are versatile drug carriers that allow effective delivery of drug to target tissue, prolong the circulation time of encapsulated drug and slowly release the drug, resulting in high levels of encapsulated drug in target tissues and a long duration of exposure of tumor cells to therapeutic drug concentrations ([@B5]; [@B1]). Vincristine sulfate liposome injection (VSLI) is an encapsulated preparation of standard VCR in liposomes, which was designed to overcome the dosing and PK limitations of conventional vincristine sulfate injection (VSI). VSLI has been studied extensively both in laboratory ([@B13]; [@B25], [@B26]; [@B14]; [@B30]; [@B20]) and in the clinic ([@B6]; [@B7]; [@B3], [@B2]; [@B18]; [@B24]; [@B27]; [@B23]; [@B4]; [@B21]) to show the superiority over standard VCR. Marqibo^®^ (Hana Biosciences, Inc.) was the first listed VSLI approved by FDA at 2012 ([@B22]). Although higher antitumor activity with good tolerance was observed for VSLI, a clear understanding of concentration-effect/toxicity relationship, the release properties of VCR from liposome and the contribution of F-VCR to the overall PK profile of T-VCR for VSLI in human being are still limited.

In the present study, a new VSLI (developed by Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.) was introduced in the phase Ia trial, which was conducted to study the PK characters of F-VCR and T-VCR, the VCR urinary excretion and the safety in Chinese subjects with malignant lymphoma after VSLI injection.

Materials and Methods {#s1}
=====================

Materials
---------

Vincristine sulfate liposome injection (0.16 mg/mL) was provided by Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co., Ltd., China, which is a three-part formulation containing empty liposomes, disodium hydrogen phosphate and VCR sulfate for injection. After the standard procedure, the encapsulation efficiency of liposomal VCR was up to 95% and liposomal VCR remains stable for at least 24 h when stored at 4°C. VSI, cytoxan (cyclophosphamide power injection), hydroxyrubicin (adriamycin power injection), oncovin (VSI) and prednisone tablets were purchased through Nanjing Pharmaceutical Hefei Tianxing Co., Ltd., China.

Study Subjects
--------------

Eligible patients aged from 18 to 65 years had histologically or cytologically confirmed malignant lymphoma, which were refractory to conventional forms of cancer therapy. They should not receive other therapy including surgery, chemotherapy or radiotherapy within at least previous 4 weeks. In addition, it was required for eligible patients to have life expectancy of at least 12 weeks, and Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate bone marrow function (leukocyte count ≥4.0 × 10^9^/L, an absolute granulocyte count ≥1.5 × 10^9^/L, a platelet count 75.0 × 10^9^/L and a hemoglobin count ≥80g/L), and adequate hepatic function (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and total bilirubin ≤3 × the upper limit of normal \[ULN\], and total bilirubin ≤1.5 × ULN), and renal function (serum creatinine ≤1.5 × ULN).

Patients with brain metastases, or CNS disorder, or severe cardiac and cerebral vascular diseases, or active infection were excluded. Patients who were allergic to the test drug and accessories were ineligible.

Study Design
------------

The study design was shown in **Figure [1](#F1){ref-type="fig"}**. In the Phase Ia study with multi-center, randomized, open-label and cross-over design, two treatments were administered under fasted conditions. The treatment sequence for each participant was assigned by a computer-generated randomization list. Treatment 1 was standard CHOP scheme including cytoxan (cyclophosphamide power injection, 750 mg/m^2^), hydroxyrubicin (adriamycin power injection, 50 mg/m^2^), oncovin (VSI, 1.4 mg/m^2^) and prednisone tablets (100 mg). The drugs for injection were administrated intravenously (I.V.) on study day 1 and the tablets were swallowed whole for concessive 5 days from day 1 to 5 of each 21-day circle. Treatment 2 was modified CHOP scheme in which VSLI (1.0 mg/m^2^) replaced VSI and others remained unchanged. VSI and VSLI should be administrated within 60 ± 5 min.

![Study design. Treatment 1, standard CHOP scheme including cytoxan (cyclophosphamide power injection, 750 mg/m^2^), hydroxyrubicin (adriamycin power injection, 50 mg/m^2^), oncovin (VSI, 1.4 mg/m^2^) and prednisone tablets (100 mg); Treatment 2, modified CHOP scheme in which VSLI (1.0mg/m^2^) replaced VSI. The drugs for injection were administrated intravenously (I.V.) on study day 1 and the tablets were swallowed whole for concessive 5 days from day 1 to 5 of each 21-day circle.](fphar-09-00991-g001){#F1}

Subjects fasted overnight for at least 10 h prior to drug administration and for at least 2 h post-dose, after which controlled food intake was allowed. Cigarette, alcohol, tea, coffee, grapefruit-, or drug-containing food or drink, and non-investigator-approved prescription medications or over-the-counter products were to be avoided at least 24 h post-dose and during the study.

Blood and Urine Sampling for PK Analyses
----------------------------------------

Blood samples were collected at pre-dosing, 15, 30, and 60 min after infusion and 0.25, 0.5, 2, 4, 8, 12, 24, 48, 72, and 96 h after the end of infusion. The whole blood was centrifuged (450 ×*g* at 4°C for 10 min) and obtained plasma then was divided into three parts. One part was used to separate F-VCR from liposomes using solid phase extraction (SPE) method immediately and the remaining two parts (one part was used as the backup) were frozen for assay of the T-VCR concentration.

Urine samples were collected from four patients of group A (one female and three males) before and after drug infusion up to 97 h at six intervals: 0--5, 5--13, 13--25, 25--49, 49--73, and 73--97 h. The samples from each interval were mixed and the volume was measured. Then 10 mL urine samples were remained and frozen at -80°C.

Bioanalytical Methods
---------------------

The plasma concentration of F-VCR and T-VCR and the urine VCR concentration was determined using the ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) system (Waters Corporation, Milford, MA, United States) with vinblastine sulfate used as the internal standard (IS) as previously described by our team ([@B29], [@B28]). The compounds were detected as doubly charged ions and the multiple reaction monitor (MRM) transitions of VCR and the IS were *m/z* 413.2 → 353.2 and *m/z* 406.2 → 271.6, respectively. F-VCR was separated from liposomal form in plasma using SPE method; plasma T-VCR and urine VCR were extracted using liquid-liquid extraction method. F-VCR and T-VCR were identified and quantified over a theoretical concentration range of 0.2--50 ng/ml for F-VCR in plasma, 0.5--400 ng/ml for T-VCR in plasma and 0.5--100 ng/ml for VCR in urine, respectively. Assay specificity was assessed using blank sample from six different lots to verify the absence of interference at retention time. Quantitation was made using peak area ratios of analyte/IS, and back-calculated concentrations were determined using a weighted (1/ × 2) linear regression (y = ax + b).

Data and Statistical Analyses
-----------------------------

The measured plasma concentration was used to obtain C~max~ and the time to reach C~max~ (T~max~) directly. The main PK parameters, calculated from the plasma concentration-time data using a non-compartmental analysis method (WinNonlin Professional Network Edition, Version 7.0, Pharsight Corp., Palo Alto, CA, United States), were elimination half-life (t~1/2~), the area under plasma concentration-time curve from zero to last time (AUC~0-t~) and from zero to infinity (AUC~0-Inf~), the mean retain time from zero to last time (MRT~0-t~) and from zero to infinity (MRT~0-Inf~), clearance (CL) and apparent volume of distribution (V~d~). Mann-Whitney test was used to compare PK parameters (C~max~, AUC~0-t~, t~1/2~, V~z~ and CL) between the two groups using GraphPad Prism software (Version 7.0). *P*-value less than 0.05 was considered to be significant.

Safety Assessments
------------------

The safety of the subjects was monitored by evaluation of physical examinations, vital signs, electrocardiograms, and clinical laboratory tests and adverse events (AEs) reporting. AEs were classified by system organ class and were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4. Safety results were analyzed using descriptive statistics.

Results
=======

Subjects
--------

There were eight patients (four males and four females) enrolled in this study. Other demographic data are shown in **Table [1](#T1){ref-type="table"}**. Nobody withdrew/were withdrawn before the end of the study. All patients were assessable for safety. All subjects provided measurable PK data and were therefore included in the PK evaluation and statistical analysis. **Table [2](#T2){ref-type="table"}** is a summary of dose level, number of the patients and actual dose delivered.

###### 

Demographic characteristics of the patients.

  ---------------------------------------------------------------------------------------
                                                  Group A\            Group B\
                                                  (*n* = 4)           (*n* = 4)
  -------------------------- -------------------- ------------------- -------------------
  Sex                                                                 

                             Male                 3                   1

                             Female               1                   3

  Age (years)                                     54.9 (45.6--62.0)   48.2 (20.0--70.3)

  Body surface area (m^2^)                        1.7 (1.3--1.8)      1.8 (1.5--1.9)

  ECOG status                                                         

                             0--1                 4                   4

                             2                    0                   0

  Tumor types                                                         

                             Malignant lymphoma   4                   4

                             Prior therapy                            

                             Surgery              2                   0

                             Chemotherapy         4                   4
  ---------------------------------------------------------------------------------------

###### 

Planned dose levels and doses delivered.

  Dose level (mg/m^2^)   Number of patients enrolled   Vincristine dose delivered (mg)   
  ---------------------- ----------------------------- --------------------------------- ------------
  1.4 VSI                8                             2.00                              2.00--2.00
  1.0 VSLI               8                             1.75                              1.33--1.89

PKs of T-VCR
------------

The mean plasma T-VCR concentration vs. time curves of patients who received VSLI (1.0 mg/m^2^) or VSI (1.4 mg/m^2^) are shown in **Figure [2](#F2){ref-type="fig"}**. The corresponding PKs of T-VCR were calculated from these data and are presented in **Table [3](#T3){ref-type="table"}**. The maximum plasma T-VCR concentrations (C~max~) were observed at the end of the VSLI infusion, subsequently a rapid distribution phase occurred, in which concentration rapidly declined within 1 h, followed by a slow distribution phase and a terminal elimination phase. Therefore, the T-VCR plasma concentrations for all subjects were characterized by a triexponential decline after treated with VSLI. Although the profiles for VSI are very similar to those for VSLI, VSI exhibited significant lower C~max~ and AUC~0-Inf~ of VCR, as well as markedly higher V~z~ and CL than those of T-VCR for VSLI. After administration of VSLI, significantly elevated systematic exposure (C~max~ was 86.6 ng/mL and AUC~0-Inf~ was 222.1 ng/mL h), associated with decreased CL (8.9 L/h) and V~z~ (224.2 L) of T-VCR were obtained, compared with those of VCR for VSI (*P* \< 0.01). There was no significant difference for half life (t~1/2~) between two groups (VSLI, 18.4 h vs. VSI, 22.5 h, *P* = 0.065).

![Mean logarithmic concentration vs. time plot of T-VCR and F-VCR following infusion of VSLI (1.0 mg/m^2^) and VCR post injection of VSI (1.4 mg/m^2^).](fphar-09-00991-g002){#F2}

PKs of F-VCR
------------

The mean plasma F-VCR concentration-time plots of patients after administration with VSLI at dose level of 1.0 mg/m^2^ is shown in **Figure [2](#F2){ref-type="fig"}**. Key PK parameters of plasma F-VCR are shown in **Table [3](#T3){ref-type="table"}**.

###### 

Main PK parameters of F-VCR and T-VCR following infusion of VSLI (1.0 mg/m^2^) and VCR post injection of VSI (1.4 mg/m^2^).

  Parameters             VSLI (1.0 mg/m^2^)   VSI (1.4 mg/m^2^)   
  ---------------------- -------------------- ------------------- ---------------
  C~max~ (ng/mL)         1.8 (0.6)            86.6 (37.4)^a^      26.6 (5.2)
  AUC~0-t~ (ng/m⋅h)      50.5 (21.8)          207.6 (86.3)^b^     74.4 (20.3)
  AUC~0-Inf~ (ng/mL⋅h)   64.8 (32.9)          222.1 (86.5)^c^     95.1 (22.1)
  T~max~ (h)             1.9 (3.0)            0.9 (0.3)           0.9 (0.2)
  t~1/2~ (h)             35.6 (16.2)          18.4 (10.2)^d^      22.5 (5.7)
  MRT~0-t~ (h)           28.7 (9.1)           8.0 (4.1)           10.6 (3.8)
  MRT~0-Inf~ (h)         50.0 (21.1)          14.1 (8.8)          24.1 (6.8)
  CL (L/h)               30.9 (11.8)          8.9 (4.2)^e^        22.1 (6.5)
  Vz (L)                 1364.9 (398)         224.1 (109)^f^      688.8 (131.2)

Values are expressed as mean (SD).

a

P = 0.0002 vs. VSI group.

b

P = 0.0006 vs. VSI group.

c

P = 0.0011 vs. VSI group.

d

P = 0.065 vs. VSI group.

e

P = 0.0006 vs. VSI group.

f

P = 0.0002 vs. VSI group.

Multiple peaks were apparently observed for the individual F-VCR concentration-time curve ([**Supplementary Material**](#SM1){ref-type="supplementary-material"}). The peak concentration (C~max~) of F-VCR was obtained at the end of VSLI infusion (1 h) in most patients (7 of 8 patients). Another one or two lower concentration peaks appeared at 9 or 3/9 h after the start of infusion. Then, the F-VCR concentration gradually declined. At 1 h after i.v. administration of VSLI, the mean plasma concentration of F-VCR was 1.8 ng/ml, compared with 86.6 ng/ml for T-VCR. This indicated that F-VCR represented 2% of the T-VCR in the plasma at this time point. The proportion of F-VCR in the plasma was evaluated by comparing the AUC values. The AUC~0-Inf~ value for F-VCR after the administration of VSLI was 64.8 ng/mL h, which represent 29.2% of the AUC~0-Inf~ for T-VCR. In addition, systemic exposure of F-VCR for VSLI was compared with that of VCR for VSI. Although the similar AUC~0-Inf~ value of F-VCR to that of VCR was obtained after dose calibration, the lower F-VCR concentration at every time point from 0.25 to 25 h after administration of VSLI than that of VCR for VSI was observed. It is important to note that the significant decreased C~max~ of F-VCR contrasts the increased plasma VCR concentration observed after VSI administration where peak value was 26.3 ng/mL, 16-fold greater than that of F-VCR.

Urinary Excretion
-----------------

The cumulative excretion percentage of VCR in urine from four patients treated with VSLI (1.0 mg/m^2^) and VSI (1.4 mg/m^2^) are shown in **Figure [3](#F3){ref-type="fig"}**, respectively. Less than 3% of the injected VSLI dose was eliminated in the urine over the 97-h period in the form of unchanged VCR and the extent of urinary excretion was similar to that after treated with VSI. Notably, though about 70% of the total amount of VCR excreted in the urine was recovered within 25 h after both VSLI and VSI administration, time course of excretion had large difference. The majority of VCR was excreted during the first few hours (40% of total VCR excretion within 0--5 h followed by 21% within 5--13 h and 14% within 13--25 h) post infusion of VSI. In contrast, the VCR excretion rate gradually increased over the 25-h period (6.2, 24, and 39% of the total amount of VCR excreted in the urine within 0--5, 5--13, and 13--25 h period, respectively) after VSLI administration.

![The cumulative urinary excretion of VCR in urine from four patients after dosing with VSLI \[1.0 mg/m^2^, **(A)**\] and VSI \[1.4 mg/m^2^, **(B)**\], respectively.](fphar-09-00991-g003){#F3}

Safety
------

Adverse events (AEs) were graded according to NCI CTCAE for Adverse Events (version 4.0). AEs mentioned in this paper refer to AEs associated with VALI or VSI (shown in **Table [4](#T4){ref-type="table"}**). Eight patients (100%) experienced AEs both in treatment 1and 2, seven (87.5%) and four (50.0%) of whom experienced grade ≥3 AE in treatment 1 and 2, respectively. Hematologic toxicity were the most frequently reported AEs (seven patients, 87.5% and eight patients, 100% in treatment 1 and 2, respectively) followed by metabolic disorder (five patients, 62.5% both in treatment 1and 2) and gastrointestinal reaction (four patients, 50% both in treatment 1and 2). Eight patients showed good tolerance using treatment 1and 2 and there was no significant difference of AEs between two treatments, showing good safety of VSLI at 1.0 mg/m^2^ dose level. No serious AEs occurred in this study.

###### 

Summary of adverse events (AEs) associated with VSLI or VSI reported by frequency.

                                                                   Grade   Treatment 1 (*n* = 8)   Treatment 2 (*n* = 8)
  ---------------------------- ----------------------------------- ------- ----------------------- -----------------------
  Hematologic disorders                                                    7                       8
                               Oligoleukocythemia                          7                       8
                                                                   4       1                       1
                                                                   3       4                       2
                               Neutropenia                                 6                       7
                                                                   4       2                       1
                                                                   3       4                       3
                               Lymphocytopenia                             5                       4
                                                                   4       0                       1
                                                                   3       2                       2
  Metabolic disorder                                                       5                       5
                               Hyperlipoidemia                             3                       4
                                                                   3       0                       1
                               Glutamic-oxaloacetic transaminase           1                       3
                               Glutamic-pyruvic transaminase               1                       3
  Gastrointestinal disorders                                               4                       4
                               Nausea                                      3                       3
                               Omitting                                    1                       1
  Nervous system disorders                                                 2                       1
                               Numbness of fingers                         1                       1
                               Headache                                    1                       0

Discussion
==========

Cross-over design was used in order to minimize the variability between the groups. CHOP or modified CHOP scheme, instead of single-agent VSLI or VSI, was applied in this study considering the patient benefit. A conservative dose of 1.0 mg/m^2^ for VSLI was selected in this study, which is approximately 1.4-fold lower than the recommended dose for traditional VCR for safety reasons, because a new VSLI may lead to unpredictable toxicity owing to different pharmaceutical characteristics, though liposomal VCR seemed to exhibit reduced toxicity in previous clinical study.

The PK characteristic of F-VCR and the release properties of VCR from the liposome in human being were studied. The significant lower C~max~ and AUC~0-Inf~ of F-VCR demonstrated that majority of the VCR was encapsulated in the liposome and the VCR was released slowly from the liposome though the sudden release was observed reflected by multiple peaks of plasma-concentration profiles.

In this study, the higher C~max~ values, longer circulation half-lives, and longer mean residence times observed with the T-VCR of VSLI, compared with VSI, were associated with a significantly higher plasma AUC values for T-VCR. This could be explained that VSLI decreases in plasma clearance rates and the volume of distribution compared with VSI. These data were very similar to those obtained from another study in China ([@B27]). In addition, the PK parameter values of T-VCR including C~max~, AUC~0-Inf~, CL and V~z~ from the present study were in consistent with those from the study mentioned above ([@B27]). However, the main PK parameters of T-VCR in this study had large difference from those reported in previous studies from United States ([@B2]) and Canada ([@B6]; [@B7]). The data, summarized in **Table [5](#T5){ref-type="table"}**, showed that the dose-normalized C~max~ and AUC~0-Inf~ value from three international studies were similar and exceeded those from this current study by approximately 5- and 30-fold, respectively. Besides, compared to the current study, the V~z~ of T-VCR in two studies from United States ([@B2]) and Canada ([@B6]) reduced by 80- and 50-fold, respectively. The CL of T-VCR reduced by 24-fold in study from United States vs. this present study. The differences in pharmaceutical property of VSLI including the ingredient and particle size uniformity of liposome, or in the patients' characteristics (race, cancer types and disease states) in the three international studies vs. the current study may be responsible for these inconsistencies. In addition, methodological differences used in different studies may contribute to the inconsistencies.

###### 

PK parameters of T-VCR from different studies.

  Drug name    Dose level (mg/m^2^)   C~max~        (ng/mL)        AUC~0-Inf~ (ng/mL⋅h)   Vz (L)       CL (L/h)   Patients information         Reference                          
  ------------ ---------------------- ------------- -------------- ---------------------- ------------ ---------- ---------------------------- ----------------------- ---------- --------------------
  VSLI         1                      86.6 (37.4)   222.1 (86.5)   224.1 (109)            8.9 (4.2)    8          Asian                        Malignant lymphoma      China      This present study
  VSLI         2                      127 (80.4)    242.9 (60.8)   309 (120)              8.7 (2.3)    6          Asian                        Advanced solid tumors   China      [@B27]
  Marqibo^®^   1                      404 (116)     6407 (2008)    2.8 (1.3)              0.36 (0.1)   7          6 Caucasian and 1 Hispanic   Metastatic melanoma     American   [@B2]
  VSLI         2                      891 (671)     6483 (613)     4.3 (0.8)              NA           2          NA                           Advanced carcinoma      Canada     [@B6]
  ONCO-TCS     1                      400 (400)     8300 (8300)    NA                     NA           4          NA                           Advanced carcinoma      Canada     [@B7]

NA, not available.

Two physical states of T-VCR exist in the circulation after VSLI administration including F-VCR (unentrapped and released from liposome) and liposome-entrapped VCR. It is theoretically agreed that F-VCR is responsible for causing toxicity and liposomal VCR accounts for providing the activity. From the safety perspective, it is essential to ensure that the plasma levels of F-VCR post injection of VSLI are comparable with or below those of VCR after treatment with VSI. Thus, it was anticipated that VCR is released from the liposome to increase the concentration of VCR in tumor site and to decrease the concentration of free drug in plasma, then the vast majority of drug present in circulation remains entrapped with liposomes. In order to confirm this hypothesis and better understand the release character of VCR from liposome of VSLI in human being, we developed an SPE method to separate the F-VCR from the liposomal VCR in plasma and the concentration of F-VCR was determined ([@B29]). Based on these data, we observed that the VCR was not released at constant speed because multiple peaks appeared in the plasma F-VCR concentration-time profile. While, the lower C~max~ showed that the release rate of VCR from lipid carrier was slow and controllable in general, even though the sudden release existed to some degree. When comparing the AUC~0-Inf~ value of F-VCR to that of T-VCR after administration with VSLI, the ratio at 29.2% indicated that there are only a small fraction of VCR released from liposome in the plasma. Furthermore, the lower F-VCR concentration in plasma for VSLI than that of VCR for VSI supplied the theoretical basis for the fact that VSLI lead to decreased toxicity compared to VSI, and this is consistent with the hypothesis.

It is expected that the excretion route of VCR released from liposome was similar to that of traditional VCR. The biliary system is the principal excretion route for traditional VCR ([@B11]). To confirm it, we developed a simple method to determine the VCR concentration in urine and calculate the cumulative excretion percentage of VCR in urine ([@B28]). Less than 3% of the administered dose of VSLI was excreted from urinary post injection and the extent was similar to that for VSI. Nevertheless, both the time course and the elimination rate were very different. The elimination percentage of 40--21--14% for VSI changed to 6.2--24--39% for VSLI at intervals of 0--5, 5--13, and 13--25 h, respectively. Considering the fact that it is impossible for liposomes to be cleared via glomerular filtration due to the size, the elimination rate of VCR from urine should entirely be determined by the release rate of VCR from liposome. Hence, the gradual increasing of excretion rate for VSLI indicated that VCR was slowly released from liposome. In a word, the above data declared that the liposomal VCR did not change the elimination route of VCR, but the elimination rate was different because of the slow release of VCR from liposome.

Vincristine sulfate liposome injection was well tolerated, no serious AEs were reported and no patient was withdrawn due to an AE during the study. The profile and frequency of AE, as well as the numbers of the patients who experienced the grade ≥3 AE for VSLI were consistent with that for conventional VSI. No additional toxicity was obs**erved even** though the 2.8-times higher plasma AUC~0-Inf~ of T-VCR for VSLI than that of VCR for VSI was obtained.

Conclusion
==========

In summary, the high exposure of T-VCR and low exposure of F-VCR demonstrated that the proportion of F-VCR was very small and most of VCR was entrapped in liposome in circulation following injection of VSLI, which explained the fact that VSLI showed higher efficacy and lower toxicity than that for VSI. VCR was released from liposome slowly, which was reflected by the low plasma concentration of F-VCR and the delayed excretion of VCR in urine. Liposomal encapsulation of VCR did not alter the extent of VCR excretion in urine, but time course changed.
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F-VCR concentration-time curve for subject 2.

###### 

Click here for additional data file.

###### 

F-VCR concentration-time curve for subject 3.
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F-VCR concentration-time curve for subject 4.
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F-VCR concentration-time curve for subject 5.
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F-VCR concentration-time curve for subject 6.
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F-VCR concentration-time curve for subject 7.
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F-VCR concentration-time curve for subject 8.
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AE

:   adverse event

AUC~0-Inf~

:   area under plasma concentration-time curve from zero to infinity

C~max~

:   maximum concentration

CHOP

:   cytoxan (cyclophosphamide power injection), hydroxyrubicin (adriamycin power injection), oncovin (vincristine sulfate injection) and prednisone tablets

CL

:   clearance

CTCAE

:   Common Terminology Criteria for Adverse Events

F-VCR

:   free vincristine

IS

:   internal standard

I.V.

:   intravenously

NCI

:   National Cancer Institute

PK

:   pharmacokinetic

SPE

:   solid phase extraction

T-VCR

:   total vincristine

UPLC-MS/MS

:   ultra-performance liquid chromatography-tandem mass spectrometry

VSI

:   vincristine sulfate injection

VSLI

:   vincristine sulfate liposomes injection

V~z~

:   distribution volume

t~1/2~

:   elimination half-life
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